Immunology R&D Day

At our 2024 R&D Day, we’re excited to share an overview of our strategy to build an industry leading immunology pipeline of oral degrader medicines with the potential to transform treatment paradigms. And we’re thrilled to unveil two first-in-class programs targeting STAT6 and TYK2, essential signaling nodes in genetically and clinically validated pathways in diseases that are undrugged or inadequately drugged by other technologies. Learn more about how we’re leveraging our disease agnostic targeted protein degradation platform to revolutionize the treatment of complex immuno-inflammatory diseases.